This review explores variability in genotoxicity data and implications for integrating non-animal methods into regulations.
This review comprehensively examines the variability and uncertainty associated with TG conform genotoxicity data and explores the respective implications for the integration of non-animal methods (NAMs) into regulatory frameworks. Historical amendments to OECD TGs are mapped to reveal the methods evolution that improves the scientific quality of the data but also explains data heterogeneity within available databases. An analysis of the major genotoxicity databases ECVAM, ISSMIC, and OASIS demonstrates substantial variability in genotoxicity calls. Using the EFSA genotoxicity database, which currently harbours the best-curated (meta-) data, we estimate that 22 to 77% of compounds exhibit similarity of replicate results below 85%, depending on the assay. Potentially most important variables statistically explaining variability and sensitivity were analysed. The practical limitations to identify them with high reliability and to define their optimum needs to be accepted as a qualitative baseline uncertainty. These findings underscore the necessity of contextualizing NAM performance evaluations within the intrinsic variability and uncertainty of animal and in vitro reference data. We propose that this variability is explicitly considered in the development and validation of NAM-based Integrated Approaches for Testing and Assessment (IATAs). This review provides a critical foundation for regulators and scientists aiming to enhance the acceptance and utility of NAMs in the assessment of genotoxicity.
No takes yet. Share an insight, caveat, or question.
Raitano et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: